Baird Medical Successfully Launches Microwave Ablation Technology in Vietnam and Argentina
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: Newsfilter
- Global Expansion Milestone: Baird Medical successfully completed its first microwave ablation procedures in Vietnam and Argentina, marking a significant advancement in its global expansion strategy and reinforcing its market leadership in minimally invasive medical technology.
- First Procedure in Vietnam: On June 18, at Lac Viet Friendship Hospital, a physician successfully performed a microwave ablation procedure to treat a benign thyroid nodule, demonstrating the technology's potential in emerging markets.
- Successful Case in Argentina: The first procedure in Argentina was completed by the head of surgery on June 15, utilizing microwave ablation for liver treatment, showcasing the effectiveness and safety of this technology in complex surgical applications.
- Technological Advantages: Microwave ablation employs a small needle-like device for treatment, offering minimal trauma and quick recovery; Baird Medical aims to provide superior treatment options through this technology, enhancing global healthcare services.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDMD
About BDMD
Baird Medical Investment Holdings Ltd is a holding company primarily engaged in the research and development, manufacture and sales of microwave ablation (MWA) medical devices. The Company’s MWA medical devices primarily include MWA needles and MWA therapeutic apparatus. The Company is also engaged in the sales of other medical devices, including catheters, ventilators, operation tables, medical gloves, syringes and other large medical machines and systems. The proprietary medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. The Company primarily conducts its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baird Medical Successfully Launches Microwave Ablation Technology in Vietnam and Argentina
- Global Expansion Milestone: Baird Medical successfully completed its first microwave ablation procedures in Vietnam and Argentina, marking a significant advancement in its global expansion strategy and reinforcing its market leadership in minimally invasive medical technology.
- First Procedure in Vietnam: On June 18, at Lac Viet Friendship Hospital, a physician successfully performed a microwave ablation procedure to treat a benign thyroid nodule, demonstrating the technology's potential in emerging markets.
- Successful Case in Argentina: The first procedure in Argentina was completed by the head of surgery on June 15, utilizing microwave ablation for liver treatment, showcasing the effectiveness and safety of this technology in complex surgical applications.
- Technological Advantages: Microwave ablation employs a small needle-like device for treatment, offering minimal trauma and quick recovery; Baird Medical aims to provide superior treatment options through this technology, enhancing global healthcare services.
See More
Baird Medical Relocates Headquarters to U.S. to Drive Global Growth
- Headquarters Relocation: Baird Medical's relocation of its global headquarters to New York aims to enhance its market position in medical technology by providing more efficient access to global healthcare investors, thereby driving commercial expansion in innovative minimally invasive ablation technologies.
- Leadership Change: The appointment of Mark Saxton as CEO of Baird Medical's U.S. subsidiary in December 2025 is set to strengthen domestic operations and market development, ensuring the company's strategic presence in a premier global healthcare and financial hub.
- Infrastructure Development: The company is progressing on schedule with its U.S. operational buildout, making strategic investments in commercial and clinical initiatives to deliver safe and effective minimally invasive treatment solutions, thereby enhancing patient outcomes and satisfaction.
- Global Market Expansion: Baird Medical leads the thyroid microwave ablation device market in China and is rapidly expanding its commercial footprint across more than 20 countries, demonstrating strong growth potential in the global medical device market.
See More
Baird Medical Reports FY 2025 Financial Results
- Financial Decline: Baird Medical reported a GAAP EPS of -$0.98 for FY 2025 with revenue of $22.5 million, a significant drop from $32.7 million in 2024, indicating major challenges in revenue generation and profitability.
- Gross Margin Erosion: The gross profit for 2025 was $18.9 million, with a gross margin of 83.8%, down from 88.2% in 2024, reflecting increased pressure on cost control and market competitiveness.
- Surge in Operating Expenses: Total operating expenses soared to $44.5 million in 2025 from $17.3 million in 2024, driven by higher selling, general and administrative, and R&D expenses, highlighting the company's ongoing investment in commercial expansion and product innovation.
- Increased R&D Investment: R&D expenses rose significantly from $6.2 million in 2024 to $20.1 million in 2025, demonstrating the company's commitment to technological innovation and product development, despite the short-term financial strain.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven challenges in Mainland China that led to reduced sales volume and pricing pressure, highlighting significant market difficulties.
- Executive Appointment: The company appointed Mark Saxton as CEO of Baird U.S. to spearhead commercial expansion in the U.S. market; with 25 years of experience in medical technology, Saxton is expected to drive new growth opportunities for the company.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025 from $6.2 million in 2024, indicating the company's commitment to product innovation and market expansion, aimed at enhancing the competitiveness of its Microwave Ablation technology.
- Widening Operating Loss: The operating loss for 2025 reached $25.6 million, significantly up from $15.3 million in 2024, reflecting the high operational costs and market pressures faced during the company's expansion efforts.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven market dynamics in Mainland China, necessitating an accelerated geographic expansion strategy to mitigate market challenges.
- Executive Appointment: The appointment of Mark Saxton as CEO of Baird U.S. is expected to enhance commercial activities in the U.S. market, leveraging his 25 years of experience to drive market penetration and technology promotion in this critical region.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025, a 225% increase from 2024, aimed at advancing microwave ablation technology and expanding market reach, underscoring the company's commitment to future growth.
- Widening Operating Loss: The company reported an operating loss of $25.6 million in 2025, significantly higher than the $15.3 million loss in 2024, reflecting the dual pressures of rising operational costs and declining revenues, necessitating strategic measures to improve financial health.
See More
Baird Medical Successfully Hosts Clinical Training in Indonesia
- Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia, aimed at enhancing the skills of local healthcare providers, thereby improving patient care quality and reinforcing its leadership position in the Southeast Asian market.
- Market Expansion Strategy: This training initiative is a key part of the company's strategic expansion into Southeast Asia, providing advanced knowledge of Microwave Ablation technology to help healthcare institutions improve treatment outcomes and meet the growing patient demand.
- Technology Promotion: Through these workshops, Baird Medical showcased its expertise in minimally invasive technology to Indonesian healthcare providers, aiming to elevate industry standards through education and training, thus increasing market acceptance of its products.
- Strengthening Regional Partnerships: The event not only fostered collaboration with Indonesian healthcare institutions but also laid the groundwork for future business expansion, demonstrating the company's commitment and long-term investment intentions in the Southeast Asian market.
See More
Baird Medical Successfully Launches Microwave Ablation Technology in Vietnam and Argentina
- Global Expansion Milestone: Baird Medical successfully completed its first microwave ablation procedures in Vietnam and Argentina, marking a significant advancement in its global expansion strategy and reinforcing its market leadership in minimally invasive medical technology.
- First Procedure in Vietnam: On June 18, at Lac Viet Friendship Hospital, a physician successfully performed a microwave ablation procedure to treat a benign thyroid nodule, demonstrating the technology's potential in emerging markets.
- Successful Case in Argentina: The first procedure in Argentina was completed by the head of surgery on June 15, utilizing microwave ablation for liver treatment, showcasing the effectiveness and safety of this technology in complex surgical applications.
- Technological Advantages: Microwave ablation employs a small needle-like device for treatment, offering minimal trauma and quick recovery; Baird Medical aims to provide superior treatment options through this technology, enhancing global healthcare services.
See More
Baird Medical Relocates Headquarters to U.S. to Drive Global Growth
- Headquarters Relocation: Baird Medical's relocation of its global headquarters to New York aims to enhance its market position in medical technology by providing more efficient access to global healthcare investors, thereby driving commercial expansion in innovative minimally invasive ablation technologies.
- Leadership Change: The appointment of Mark Saxton as CEO of Baird Medical's U.S. subsidiary in December 2025 is set to strengthen domestic operations and market development, ensuring the company's strategic presence in a premier global healthcare and financial hub.
- Infrastructure Development: The company is progressing on schedule with its U.S. operational buildout, making strategic investments in commercial and clinical initiatives to deliver safe and effective minimally invasive treatment solutions, thereby enhancing patient outcomes and satisfaction.
- Global Market Expansion: Baird Medical leads the thyroid microwave ablation device market in China and is rapidly expanding its commercial footprint across more than 20 countries, demonstrating strong growth potential in the global medical device market.
See More
Baird Medical Reports FY 2025 Financial Results
- Financial Decline: Baird Medical reported a GAAP EPS of -$0.98 for FY 2025 with revenue of $22.5 million, a significant drop from $32.7 million in 2024, indicating major challenges in revenue generation and profitability.
- Gross Margin Erosion: The gross profit for 2025 was $18.9 million, with a gross margin of 83.8%, down from 88.2% in 2024, reflecting increased pressure on cost control and market competitiveness.
- Surge in Operating Expenses: Total operating expenses soared to $44.5 million in 2025 from $17.3 million in 2024, driven by higher selling, general and administrative, and R&D expenses, highlighting the company's ongoing investment in commercial expansion and product innovation.
- Increased R&D Investment: R&D expenses rose significantly from $6.2 million in 2024 to $20.1 million in 2025, demonstrating the company's commitment to technological innovation and product development, despite the short-term financial strain.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven challenges in Mainland China that led to reduced sales volume and pricing pressure, highlighting significant market difficulties.
- Executive Appointment: The company appointed Mark Saxton as CEO of Baird U.S. to spearhead commercial expansion in the U.S. market; with 25 years of experience in medical technology, Saxton is expected to drive new growth opportunities for the company.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025 from $6.2 million in 2024, indicating the company's commitment to product innovation and market expansion, aimed at enhancing the competitiveness of its Microwave Ablation technology.
- Widening Operating Loss: The operating loss for 2025 reached $25.6 million, significantly up from $15.3 million in 2024, reflecting the high operational costs and market pressures faced during the company's expansion efforts.
See More
Baird Medical Reports 2025 Financial Results and Strategic Updates
- Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven market dynamics in Mainland China, necessitating an accelerated geographic expansion strategy to mitigate market challenges.
- Executive Appointment: The appointment of Mark Saxton as CEO of Baird U.S. is expected to enhance commercial activities in the U.S. market, leveraging his 25 years of experience to drive market penetration and technology promotion in this critical region.
- Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025, a 225% increase from 2024, aimed at advancing microwave ablation technology and expanding market reach, underscoring the company's commitment to future growth.
- Widening Operating Loss: The company reported an operating loss of $25.6 million in 2025, significantly higher than the $15.3 million loss in 2024, reflecting the dual pressures of rising operational costs and declining revenues, necessitating strategic measures to improve financial health.
See More
Baird Medical Successfully Hosts Clinical Training in Indonesia
- Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia, aimed at enhancing the skills of local healthcare providers, thereby improving patient care quality and reinforcing its leadership position in the Southeast Asian market.
- Market Expansion Strategy: This training initiative is a key part of the company's strategic expansion into Southeast Asia, providing advanced knowledge of Microwave Ablation technology to help healthcare institutions improve treatment outcomes and meet the growing patient demand.
- Technology Promotion: Through these workshops, Baird Medical showcased its expertise in minimally invasive technology to Indonesian healthcare providers, aiming to elevate industry standards through education and training, thus increasing market acceptance of its products.
- Strengthening Regional Partnerships: The event not only fostered collaboration with Indonesian healthcare institutions but also laid the groundwork for future business expansion, demonstrating the company's commitment and long-term investment intentions in the Southeast Asian market.
See More
